Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure.

In conclusion, our study shows that AS-IV inhibits ventricular remodeling, improves cardiac function, and decreases FFA concentration of CHF model rats. Our findings suggest a therapeutic potential of using AS-IV in CHF. PMID: 29301869 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29301869?dopt=Abstract

Source: Bioscience Reports - January 4, 2018 Category: Biomedical Science Authors: Tang B, Zhang JG, Tan HY, Wei XQ Tags: Biosci Rep Source Type: research